Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells

Menopause International

Volumn 9, Issue 1, 2003, Pages 36-38

  Seeger, Harald ^a   Wallwiener, Diethelm ^a   Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer; MCF 7 cells; oestradiol; progestogens; proliferation

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RISK; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; POSTMENOPAUSE;

BREAST; CELL DIVISION; CELLS, CULTURED; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; PROGESTERONE;

EID: 12244279057     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1177/136218070300900111     Document Type: Article

References (23)

1. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333.
2. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–491.
3. Ross RK, Paganini-Hill A Wan PC Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–332.
4. Newcomb PA, Titus-Ernsthoff L Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 593–600.
5. Andreotti PE, Thornthwaite JT, Morse IS. ATP Tumor Chemosensitivity Assay. In: Stanley PE, Kricka LJ,(eds. ). Bioluminescence and Chemiluminescence: Current Status. Chichester: J. Wiley & Sons, 1991: 417–420.
6. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339–344.
7. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985; 44: 622–626.
8. Svensson LO, Johnson SH, Olsson SE. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera, and Divina. A randomised, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994; 18: 229–238.
9. Stanczyk FZ, Brenner PF, Mishell DR, et al. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978; 18: 615–633.
10. Schatz RW, Soto AM, Sonnenschein C. Effects of interaction between estradiol-17 beta and progesterone on the proliferation of cloned breast tumor cells. J Cell Physiol 1985; 124: 386–390.
11. Schoonen WGEJ, Joosten JWH, Klooosterboer HJ. Effects of two classes of progestagens pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55: 423–437.
12. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992; 52: 6539–6546.
13. van der Burg B Kalkhoven E Isbrücker L DeLaat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol 1992; 42: 457–465.
14. Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995; 15: 2551–2556.
15. Lippert C, Seeger H, Wallwiener D, Mueck AO. The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment. Eur J Gynaecol Oncol 2001; 22: 331–335
16. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Brit J Cancer 1993, 67: 945–952.
17. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69: 963–969.
18. Hargreaves DF, Knox F, Swindell R, et al. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer 1998; 78: 945–949.
19. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559–65.
20. Wang S, Counterman LJ, Haslam SZ. Progesterone action in normal mouse mammary gland. Endocrinology 1990; 127: 2183–2189.
21. Cline JM, Soderqvist G, von Schoultz E, et al. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Br Cancer Res Treat 1998; 48: 221–229.
22. Woodward TL, Xie JW, Haslam SZ. The role of mammary stroma in modulating the proliferative response to ovarian hormones in the normal mammary gland. J Mammary Gland Biol Neoplasia 1998; 3: 117–131.
23. Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998; 3: 215–25.